

See today's BioWorld

To read the full story, [subscribe](#) or [sign in](#).

Kither developing therapies for cystic fibrosis, IPF with €18.5M series B

By [Nuala Moran](#) March 16, 2022

While full details of the underlying science are due to be published in a peer reviewed journal, Kither Biotech Srl has announced its closure of an €18.5 million (US\$20.4 million) series B financing with which it aims to translate its approach to rare respiratory diseases into the clinic.

[BioWorld](#)[Financings](#)[Respiratory](#)[Series B](#)